Newton Biocapital is a life science VC focused on early-stage companies in Europe and Japan addressing chronic health conditions. It entered Bioxodes' €5.5M Series A extension as a new investor in December 2025.
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.